BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36219975)

  • 1. Recent Advances in Castleman Disease.
    Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
    Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Castleman disease.
    Dispenzieri A; Fajgenbaum DC
    Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
    Milota T; Střížová Z; Sobotková M; Bartůňková J
    Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
    Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
    González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
    Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
    Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Castleman Disease.
    Simpson D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
    Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
    Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
    Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
    Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.